Indivior Pharmaceuticals, Inc. Revenue From Performance Obligations Satisfied Or Partially Satisfied In Previous Periods
Indivior Pharmaceuticals, Inc. (INDV) reported Revenue From Performance Obligations Satisfied Or Partially Satisfied In Previous Periods of $0 for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-06.
Discontinued › Income Statement › Other Income
ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods · last filed 2024-03-06
| Period end | Revenue From Performance Obligations Satisfied Or Partially Satisfied In Previous Periods 12 month |
|---|---|
| 2023-12-31 | $0.00 20-F · filed 2024-03-06 |
| 2022-12-31 | $14.00M 20-F · filed 2024-03-06 |
| 2021-12-31 | $24.00M 20-F · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |